editor@jprims.in
9343055451
e-ISSN: 3049-1681
logo

Journal of Pharmaceutical Research and Integrated Medical Sciences

LoginTrack

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

Volume 3, Issue 2 - 2026 (JPRIMS, Vol-3, Issue-02, Feb.-2026)

Volume 3 Issue 2 Cover

Issue Details:

Volume 3 Issue 2
Published:Invalid Date

Editorial: JPRIMS, Vol-3, Issue-02, Feb.-2026

Welcome to the 2026 issue of Journal of Pharmaceutical Research and Integrated Medical Sciences. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Arpan Kumar Tripathi
Editor-in-Chief
Journal of Pharmaceutical Research and Integrated Medical Sciences

Articles in This Issue

Showing 6 of 6 articles
Research PaperID: jprims-00000213

Realizing the Promise of Cancer Nanotechnology: From Therapeutic Platforms to Omics-Driven Precision Oncology and Clinical Translation

Gokul Dewangan, Neeraj Kumar, Vivek Sahu Sahu, Gitanjali Kashyap, Vinay Sagar Verma Verma

Background: Cancer remains one of the leading causes of morbidity and mortality worldwide, with conventional treatment strategies limited by systemic toxicity, therapeutic resistance, and tumor heterogeneity. The emergence of nanotechnology offers innovative solutions to these challenges, enabling targeted drug delivery, controlled release, and theranostic integration.Objective: This review synthesizes recent progress in cancer nanomedicine, highlighting therapeutic platforms, omics-driven personalization, and clinical translation between 2019 and 2024.Methos: We discuss the major classes of therapeutic nanoplatforms including lipid-based systems, polymeric nanocarriers, inorganic nanoparticles, and hybrid or bioinspired designs detailing their mechanisms of action in targeted delivery, photothermal therapy, and multimodal treatment. Advances in genomics, transcriptomics, proteomics, and metabolomics are explored for their role in guiding nanocarrier design, with emphasis on artificial intelligence–enabled multi-omics integration for precision oncology. Clinical trial progress across liver, lung, pancreatic, breast, and brain cancers demonstrates improved tolerability, patient quality of life, and incremental survival gains, though translation remains constrained by tumor heterogeneity, blood–brain barrier penetration, scalability, cost, and regulatory hurdles.Conclusion: Cancer nanomedicine stands at a pivotal juncture advancing beyond incremental improvements to become a cornerstone of precision oncology. By uniting nanoscale engineering, multi-omics, artificial intelligence, and innovative clinical strategies, the field holds the potential to transform cancer therapy in the decade ahead.

batches.effectivenessbumpingqualityW/O emulsionmultiprotective effects+3 more
12,105 views
3,622 downloads
DOI:
10.64063/3049-1681.vol.3.issue2.1

Contributors:

 Gokul Dewangan
,
 Neeraj Kumar
,
 Vivek Sahu Sahu
,
 Gitanjali Kashyap
,
 Vinay Sagar Verma Verma
Research PaperID: jprims-00000214

Systematic Review of Smart Nanoplatforms in Liver, Breast, Kidney, and Brain Cancers: Targeted Delivery, Omics, and Therapy Response

Niharika Tiwari Tiwari, Mohit Kumar Sahu Sahu, Gitanjali Kashyap Kashyap, Aakansha Pandey Pandey, Vinay Sagar Verma Verma

Background: Liver, breast, kidney, and brain cancers remain major contributors to global cancer morbidity and mortality. Conventional therapies are limited by systemic toxicity, drug resistance, and tumor heterogeneity. Smart nanoplatforms offer targeted delivery, controlled release, and theranostic capabilities to address these challenges. Objective: This systematic review evaluates the development and clinical translation of smart nanoplatforms between 2019 and 2024, focusing on their design, omics integration, therapy response, and clinical outcomes in liver, breast, kidney, and brain cancers. Methods: Studies published between 2019 and 2024 were systematically analyzed, encompassing preclinical research, clinical trials, and multi-omics-guided nanoparticle strategies. Nanoplatforms were categorized into lipid-based, polymeric, inorganic, and hybrid/bioinspired systems. The review highlights therapy response, biomarker monitoring, and adaptive approaches informed by omics data. Results: Lipid-based and polymeric nanoparticles demonstrated enhanced tumor targeting and reduced systemic toxicity. Inorganic and hybrid/bioinspired platforms enabled imaging-guided therapy and immune evasion. Integration of genomics, transcriptomics, proteomics, and metabolomics with AI-driven analytics facilitated personalized therapy and adaptive treatment strategies. Clinical trials reported improved patient tolerability, quality of life, and preliminary survival benefits, though translational barriers—including tumor heterogeneity, blood–brain barrier penetration, manufacturing, and regulatory hurdles—remain significant. Conclusions: Smart nanoplatforms represent a transformative approach to precision oncology. The combination of targeted delivery, multi-omics guidance, and AI-driven therapy optimization has the potential to enhance treatment efficacy and patient-specific outcomes. Future research should focus on scalable manufacturing, regulatory standardization, and integration of innovative trial designs to accelerate clinical adoption.

Cancer NanomedicineNanotechnology Therapeutic PlatformsLipid NanoparticlesPolymeric NanocarriersInorganic NanoparticlesBioinspired Nanosystems+8 more
12,262 views
3,815 downloads
DOI:
10.64063/3049-1681.vol.3.issue2.2

Contributors:

 Niharika Tiwari Tiwari
,
 Mohit Kumar Sahu Sahu
,
 Gitanjali Kashyap Kashyap
,
 Aakansha Pandey Pandey
,
 Vinay Sagar Verma Verma
Research PaperID: jprims-00000215

Biodegradable Polymers in Drug Delivery: Design, Degradation, and Drug Release Dynamics

Gitanjali Kashyap, Aakansha Pandey Pandey, Mohit Kumar Sahu, Bhushan Lal Lal, Vinay Sagar Verma Verma

Biodegradable polymers have emerged as essential components in advanced drug delivery systems, enabling controlled, sustained, and site-specific therapeutic release while minimizing systemic toxicity. This comprehensive review covers the design principles, degradation mechanisms, and drug release dynamics of natural and synthetic biodegradable polymers such as PLGA, PCL, chitosan, and alginate. Their adaptability allows fabrication into nanoparticles, microspheres, hydrogels, and scaffolds tailored to various clinical needs, including cancer therapy, vaccine delivery, gene therapy, and tissue engineering. The review discusses hydrolytic and enzymatic degradation processes, surface versus bulk erosion behaviors, and factors influencing polymer degradation and drug release kinetics. Case studies highlight FDA-approved formulations leveraging these polymers for enhanced therapeutic efficacy and patient compliance. Challenges such as variability in degradation rates, formulation stability, manufacturing scale-up, and regulatory hurdles are addressed. Emerging frontiers in smart stimuli-responsive systems, hybrid polymers, AI-driven design, and personalized medicine underscore the future potential of biodegradable polymers as cornerstones of precision and sustainable therapeutics.

Cancer nanomedicineTargeted deliverySmart nanoplatformsOmicsPrecision oncologyTherapy response
12,765 views
3,869 downloads
DOI:
10.64063/3049-1681.vol.3.issue2.3

Contributors:

 Gitanjali Kashyap
,
 Aakansha Pandey Pandey
,
 Mohit Kumar Sahu
,
 Bhushan Lal Lal
,
 Vinay Sagar Verma Verma
Research PaperID: jprims-00000216

Comparative Evaluation of Polymeric, Nanoparticle, and Hydrogel Based Colon-Targeted Drug Delivery Systems under Simulated Gastrointestinal Conditions

P.Krishna Prasanna Prasanna, Kondru Sruthi Sruthi, D.Lalitha Sree Vani Vani, K. Sampath Kumar Kumar

The present study compares three colon-targeted drug delivery systems; Eudragit S100-coated polymeric tablets, PLGA nanoparticles, and alginate hydrogel microspheres, developed for the controlled release of 5-Fluorouracil (5-FU). Each formulation was prepared and optimized using distinct carriers and evaluated under simulated gastrointestinal (GI) conditions to assess their physicochemical characteristics, release behaviour, and stability. The formulations were characterized for particle size, surface charge, encapsulation efficiency, and swelling index. Morphological analysis confirmed smooth coating in polymeric tablets, spherical uniformity in nanoparticles, and a porous structure in hydrogels. In vitro dissolution studies revealed minimal drug release in gastric conditions (≤2% at pH 1.2) and sustained release at colonic pH (7.4). PLGA nanoparticles showed the most controlled release profile, achieving 92.1 ± 2.4% cumulative release at 24 hours, compared with 100.0 ± 3.1% for polymeric tablets and 85.4 ± 2.1% for hydrogels. Kinetic modeling indicated that all systems followed diffusion-dominated release, with nanoparticles best fitting the Higuchi model (R² = 0.981). Stability studies confirmed nanoparticle integrity under prolonged acidic and neutral exposure, while hydrogels exhibited partial deformation. Overall performance analysis identified PLGA nanoparticles as the most efficient system, demonstrating superior acid resistance, encapsulation efficiency, and colon-specific release. These findings suggest that nanoparticle-based carriers offer significant potential for achieving predictable, site-specific, and sustained drug delivery to the colon.

Pharmaceutical Formulation.Personalized MedicineStimuli-Responsive PolymersPolymeric MicrospheresPLGANanoparticles+4 more
12,628 views
3,858 downloads
DOI:
10.64063/3049-1681.vol.3.issue2.4

Contributors:

 P.Krishna Prasanna Prasanna
,
 Kondru Sruthi Sruthi
,
 D.Lalitha Sree Vani Vani
,
 K. Sampath Kumar Kumar
Research PaperID: jprims-00000217

Meta-Analysis of Multi-Omics and Nanoparticle-Enhanced Therapeutics in Solid Tumors: Advancing Precision Oncology

Gitanjali Kashyap, Aakansha Pandey Pandey, Niharika Tiwari Tiwari, Mohit Kumar Sahu, Vinay Sagar Verma

Background: Solid tumors remain among the leading causes of global cancer mortality, with limited therapeutic options due to drug resistance, toxicity, and tumor heterogeneity. The convergence of nanomedicine and multi-omics technologies offers a novel strategy for precision oncology, enabling targeted drug delivery, biomarker-guided therapy, and improved monitoring of treatment response. Objectives: This meta-analysis aimed to synthesize evidence from 2019 to 2024 on the efficacy, safety, and biomarker integration of nanoparticle-enhanced therapeutics combined with multi-omics approaches in solid tumors, including liver, breast, lung, kidney, brain, and pancreatic cancers. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted following PRISMA guidelines. Eligible studies (2019–2024) reporting clinical or translational outcomes of nanoplatform-based therapies with omics-guided integration were included. Data were extracted on study design, sample size, tumor types, nanoparticle platforms, omics biomarkers, efficacy outcomes (response rates, progression-free survival [PFS], overall survival [OS]), and toxicity. Pooled analyses were performed using random-effects models. Results: A total of 62 studies comprising ~8,500 patients were included. Lipid-based (38%), polymeric (27%), inorganic (21%), and bioinspired/hybrid (14%) nanoplatforms were evaluated across multiple solid tumors. Pooled analysis demonstrated an improved overall response rate (ORR: 48% vs. 32%, pConclusions: Nanoparticle-enhanced therapeutics integrated with multi-omics approaches show significant promise in improving survival, reducing toxicity, and enabling biomarker-driven precision oncology in solid tumors. However, translational barriers—including tumor heterogeneity, blood–brain barrier penetration, and manufacturing scalability—must be overcome for widespread adoption. The future lies in AI-integrated, stimuli-responsive, bioinspired nanoplatforms guided by multi-omics data, supported by innovative trial designs to ensure clinical translation and equitable global access.

Colon-targeted drug deliveryPLGA nanoparticlesEudragit S100-coated tabletsalginate hydrogel microspheres5-Fluorouracil (5-FU)pH-dependent release+3 more
12,662 views
3,886 downloads
DOI:
10.64063/3049-1681.vol.3.issue2.5

Contributors:

 Gitanjali Kashyap
,
 Aakansha Pandey Pandey
,
 Niharika Tiwari Tiwari
,
 Mohit Kumar Sahu
,
 Vinay Sagar Verma
Research PaperID: jprims-00000218

Traditional Medicine in Indian Knowledge Systems: Insights and Evidence for Managing Metabolic Disorders

G. Neethirajan Neethirajan

Obesity, dyslipidemia, and type 2 diabetes are examples of metabolic disorders that pose serious worldwide health risks. These conditions are typified by oxidative stress, persistent low-grade inflammation, and disturbed lipid and glucose metabolism. The study of complementary and alternative methods has been prompted by the fact that, despite their effectiveness, conventional pharmaceutical treatments are frequently constrained by side effects, high prices, and incomplete efficacy. With an emphasis on holistic and multi-targeted therapies using single herbs and polyherbal combinations, traditional Indian medical systems, especially Ayurveda, offer a centuries-old storehouse of botanical knowledge. Numerous preclinical investigations in animal models show that these plant-based treatments can improve overall metabolic homeostasis by regulating important molecular pathways like PPARs, AMPK, and GLUT4, suppressing pro-inflammatory cytokines, enhancing antioxidant defenses, and modulating lipid and glucose metabolism. Synergistic effects are sometimes seen in polyherbal formulations, which provide better benefits across several physiological pathways than single-plant therapies. Although these results demonstrate the therapeutic value of Ayurvedic treatments and their conformity to contemporary scientific concepts, issues with standardization, mechanistic clarification, and comparative effectiveness with mainstream medications still exist. A promising framework for the creation of safe, efficient, and evidence-based phytotherapeutics to control the rising worldwide burden of metabolic illnesses is provided by combining traditional Indian medical knowledge with modern research.

Cancer NanomedicineSolid TumorsMulti-OmicsNanoparticlesPrecision OncologyTherapy Response+1 more
13,027 views
3,845 downloads
DOI:
10.64063/3049-1681.vol.3.issue2.6

Contributors:

 G. Neethirajan Neethirajan

Related Issues

Volume 3, Issue 6

2026 • 9 articles

Volume 3, Issue 5

2026 • 21 articles

Volume 3, Issue 4

2026 • 7 articles

Volume 3, Issue 3

2026 • 8 articles